US Patent

US9901640 — Controlled release formulations of levodopa and uses thereof

Method of Use · Assigned to Impax Laboratories LLC · Expires 2028-12-26 · 3y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a modified release dosage form of levodopa.

USPTO Abstract

A modified release levodopa dosage form.

Drugs covered by this patent

Sinemet Cr (CARBIDOPA) · Aton

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr
`U-219`	—	Sinemet Cr

Patent Metadata

Patent number: US9901640
Jurisdiction: US
Classification: Method of Use
Expires: 2028-12-26
Drug substance claim: No
Drug product claim: Yes
Assignee: Impax Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.